Business Context and Reporting Period
This Form 8-K was filed by TherapeuticsMD, Inc. on January 6, 2016, reporting the entry into a material definitive agreement. The Company is a Nevada corporation headquartered in Boca Raton, Florida.
Key Financial Metrics
The filing details a capital raise event rather than operational financial performance metrics such as revenue or profit.
- Offering Size: 15,151,515 shares of Common Stock.
- Offering Price: $8.25 per share.
- Over-Allotment Option: Underwriters were granted a 30-day option for up to 2,272,727 additional shares, which was exercised in full.
- Net Proceeds: Approximately $134.9 million (after underwriting discounts, commissions, and estimated offering expenses).
- Expected Closing Date: January 12, 2016.
Material Changes
The primary material change is the execution of an underwriting agreement with Goldman, Sachs & Co. and Cowen and Company, LLC. This transaction significantly increases the Company's liquidity through the issuance of new equity. The filing does not provide comparative financial data against prior periods as it is a current report on a specific event.
Outlook, Risks, and Management Commentary
The offering was conducted pursuant to an effective shelf registration statement on Form S-3. The Underwriting Agreement includes customary representations, warranties, covenants, and indemnification rights. The filing does not contain specific forward-looking guidance on future revenue or earnings, nor does it detail specific risks beyond those customary for underwritten public offerings.
Investor Verification Checklist
- Verify the final closing of the offering on or around January 12, 2016.
- Confirm the total number of shares issued, including the full exercise of the 2,272,727 share over-allotment option.
- Review the final prospectus supplement filed on January 7, 2016, for updated use of proceeds.
- Examine the Underwriting Agreement (Exhibit 1.1) for specific lock-up provisions or covenants.